Sökning: WFRF:(Rosenqvist Mårten)
> (2010-2014) >
The safety of fleca...
The safety of flecainide treatment of atrial fibrillation : long-term incidence of sudden cardiac death and proarrhythmic events
-
- Almroth, Henrik, 1970- (författare)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Department of Cardiology, Örebro University Hospital, Örebro, Sweden
-
- Andersson, Tommy (författare)
- Department of Cardiology, Örebro University Hospital, Örebro, Sweden
-
- Fengsrud, Espen, 1970- (författare)
- Örebro universitet,Institutionen för hälsovetenskaper,Department of Cardiology, Örebro University Hospital, Örebro, Sweden
-
visa fler...
-
- Friberg, Leif (författare)
- Karolinska Institutet
-
- Linde, P. (författare)
- Department of Cardiology, Örebro University Hospital, Örebro, Sweden
-
- Rosenqvist, Mårten (författare)
- Karolinska Institutet
-
- Englund, A. (författare)
- Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2011-06-02
- 2011
- Engelska.
-
Ingår i: Journal of Internal Medicine. - : John Wiley & Sons. - 0954-6820 .- 1365-2796. ; 270:3, s. 281-290
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective:To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) andproarrhythmic events.Design: Retrospective,observational cohort study.Setting.Single-centre study at Örebro University Hospital, Sweden.Setting: Single-centre study at Orebro University Hospital, Sweden.Subjects: A total of 112 patients with paroxysmal (51%) or persistent (49%) AF (mean age 60 ± 11 years) were included after identifying all patients with AF who initiated oral flecainide treatment (mean dose 203 ± 43 mg per day) between 1998 and 2006. Standard exclusion⁄inclusion criteria for flecainide were used,andflecainidetreatmentwasusually combined withanatrioventricular-blocking agent (89%).Main outcome measure: Death was classified as sudden or nonsudden according to standard definitions. Proarrhythmia was defined as cardiac syncope or lifethreatening arrhythmia.Results: Eight deaths were reported during a mean follow- up of 3.4 ± .4 years. Compared to the general population, the standardized mortality ratios were 1.57 (95% confidence interval (CI) 0.68–3.09) for allcause mortality and 4.16 (95% CI 1.53–9.06) for death from cardiovascular disease. Three deaths were classified as SCDs. Proarrhythmic events occurred in six patients (two each with wide QRS tachycardia, 1 : 1 conducted atrial flutter and syncope during exercise).Conclusion: We found an increased incidence of SCD or proarrhythmic events in this real-world study of flecainide used for the treatment of AF. The findings suggest that further investigation into the safety of flecainide for the treatment of patients with AF is warranted.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Nyckelord
- atrial fibrillation
- flecainide
- proarrhythmia
- safety
- sudden cardiac death
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas